The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
New England Journal of MedicinePublished 2 September 1999Open access
Bertram Pitt, Faı̈ez Zannad, Willem J. Remme, Robert Cody, A Castaigne, A.J. Pérez Pérez
Citations8,985
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Abstract
Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Keywords
Medicine
Springer series in statisticsNonparametric Estimation from Incomplete Observations
45,533 Citations1992Edward L. Kaplan, Paul Meier
Journal of the Royal Statistical Society Series B (Statistical Methodology)Regression Models and Life-Tables
39,259 Citations1972D. R. Cox
New England Journal of MedicineEffect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
8,006 Citations1991The SOLVD Investigators*
The addition of enalapril to conventional therapy significantly reduced mortality and hospitalizations for heart failure in patients with chronic congestive heart failure and reduced ejection fractions.
Journal of the American Statistical AssociationNonparametric Estimation from Incomplete Observations
7,727 Citations1958Edward L. Kaplan, Paul Meier
New England Journal of MedicineEffects of Enalapril on Mortality in Severe Congestive Heart Failure
5,077 Citations1987The Consensus Trial Study Group*
It is concluded that the addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms and a significant improvement in NYHA classification was observed in the enAlapril group.
The LancetThe Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
4,913 Citations1999Lechat, P, Brunhuber, Kw +280 more
Beta-blocker therapy had benefits for survival in stable heart-failure patients and should not be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients.
New England Journal of MedicineThe Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
4,656 Citations1996Milton Packer, Michael R. Bristow +5 more
Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor.
The American Journal of CardiologyEffects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
3,778 Citations1988Karl Swedberg, John Kjekshus
The addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms, and the effect seems to be due to a reduction in death from progression of heart failure.
BiometricsA Multiple Testing Procedure for Clinical Trials
3,349 Citations1979Peter C. O’Brien, Thomas R. Fleming
The overall size of the procedure is shown to be controlled with virtually the same accuracy as the single sample chi-square test based on N(m1 + m2) observations and the power is found to bevirtually the same.
New England Journal of MedicineThe Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure
2,968 Citations1997The Digitalis Investigation Group
Digoxin did not reduce overall mortality, but it reduced the rate of hospitalization both overall and for worsening heart failure, which defines more precisely the role of digoxin in the management of chronic heart failure.
CirculationPathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.
2,029 Citations1991K. T. Weber, Christian G. Brilla
It can be concluded that arterial hypertension together with elevated circulating aldosterone are associated with cardiac fibroblast involvement and the resultant heterogeneity in tissue structure and the stage is set to prevent pathological LVH resulting from myocardial fibrosis as well as to reverse it.
BiometrikaDiscrete sequential boundaries for clinical trials
1,740 Citations1983K. K. Gordon Lan, David L. DeMets
A more flexible way to construct discrete sequential boundaries is proposed, based on the choice of a function, a*(t), which characterizes the rate at which the error level ac is spent.
New England Journal of MedicineEffect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure
1,183 Citations1996Milton Packer, Christopher M. O’Connor +10 more
A new calcium-channel blocker, amlodipine, did not increase cardiovascular morbidity or mortality in patients with severe chronic heart failure and the possibility that amlidipine prolongs survival in Patients with nonischemic dilated cardiomyopathy requires further study.
CirculationHormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.
1,152 Citations1990Karl Swedberg, P. Eneroth +2 more
There is a pronounced but variable neurohormonal activation in heart failure even in patients with similar clinical findings, and the effect of enalapril on mortality is related to hormonal activation in general and the renin-angiotensin system in particular.
The LancetQT dispersion and sudden unexpected death in chronic heart failure
770 Citations1994Craig Barr, A. A O Naas +3 more
The association of increased QT dispersion with sudden death suggests that patients at high risk of such death could be identified by means of this simple, reproducible test.
Circulation ResearchRemodeling of the rat right and left ventricles in experimental hypertension.
676 Citations1990Christian G. Brilla, R Pick +3 more
In experimental arterial hypertension in the rat, myocyte and nonmyocyte compartments of the myocardium are under separate controls: myocyte hypertrophy is most closely related to ventricular loading while circulating AII and AL, acting alone or in concert with other humoral factors, regulate the accumulation of collagen within the right and left ventricles.
HypertensionMineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
493 Citations1998Ricardo Rocha, Praveen Chander +3 more
Observations indicate a vascular and end organ protective effect of spironolactone in the absence of lowered blood pressure in saline-drinking stroke-prone spontaneously hypertensive rats and are consistent with a major role for mineralocorticoids as hormonal mediators of vascular injury.
The American Journal of CardiologyEffectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])**See Appendix for full list of RALES investigators.
482 Citations1996
Daily doses of 12.5 to 25 mg of spironolactone coadministered with conventional therapy of ACE inhibitors, loop diuretics, and digitalis are relatively safe (provided that serum potassium levels are monitored) and effective in blocking the effects of aldosterone, while reducing the potential for hypokalemia in patients with heart failure.
Journal of Molecular and Cellular CardiologyAnti-Aldosterone Treatment and the Prevention of Myocardial Fibrosis in Primary and Secondary Hyperaldosteronism
424 Citations1993Christian G. Brilla, Luiz Shiguero Matsubara +1 more
Myocardial fibrosis was comparable in primary or secondary hyperaldosteronism, wherein elevations in plasma aldosterone, relative to increased sodium intake, are associated with arterial hypertension and the competitive ALDO receptor antagonist, spironolactone, was able to prevent fibrosis in either model irrespective of the development of LVH and the presence of hypertension.
HeartCaptopril in heart failure. A double blind controlled trial.
378 Citations1984John G.F. Cleland, Henry J. Dargie +8 more
Captopril seemed to be of considerable value in the long term treatment of severe cardiac failure in a double blind trial.
BiometricsSample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials
353 Citations1988Edward Lakatos
A method of estimating sample sizes for the comparison of survival curves by the log-rank statistic in the presence of unrestricted rates of noncompliance, lag time, and so forth is presented.
Journal of Pharmacology and Experimental TherapeuticsThree new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
342 Citations1987Marc de Gasparo, Urs R. Joss +8 more
It appears that the 9 alpha, 11 alpha-position of the steroid structure is a site of the molecule which can be modified to improve the specificity of aldosterone-antagonists not only in vitro, but also in vivo.
Cardiovascular ResearchAldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients
337 Citations1997R. MacFadyen
These are the first human data to show that use of the aldosterone antagonist, spironolactone, can positively improve time-domain heart rate variability and reduce myocardial collagen turnover, as reflected by further reductions in serum procollagen peptide, despite concurrent ACE inhibitor treatment.
Journal of EndocrinologyRISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION
335 Citations1981Jan A. Staessen, Paul Lijnen +3 more
The plasma concentration of aldosterone was followed in seven hypertensive patients before and during long-term angiotensin II suppression with the orally active ang Elliotensin-I-converting-enzyme inhibitor, captopril to find the mechanism responsible for the late rise of the plasma concentration.
New England Journal of MedicineThe Management of Chronic Heart Failure
329 Citations1996Jay N. Cohn
Treatment to prevent or delay the progression of left ventricular dysfunction may be quite different from that to treat symptoms of heart failure.
The American Journal of CardiologyEffects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease
316 Citations1995Craig Barr, Chim C. Lang +4 more
The principal finding is that cardiac norepinephrine uptake as assessed by 123I-metaiodobenzylguanidine scintigraphy increased with spironolactone, which is a good result for patients with New York Heart Association II to III congestive heart failure.
The American Journal of CardiologyEfficacy and tolerance of spironolactone in essential hypertension
268 Citations1987Xavier Jeunemaı̂tre, Gilles Châtellier +6 more
It is concluded that spironolactone administered in daily practice reduced BP without inducing adverse metabolic adverse effects and that in patients with essential hypertension, doses should be kept below 100 mg.
PubMedAntihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.
238 Citations1983Jérôme Biollaz, Hans R. Brunner +3 more
Journal of Cardiac FailureAldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
224 Citations1996Allan D. Struthers
It may well be that residual aldosterone mediates many harmful effects in chronic heart failure and that to optimize the benefit of blocking the renin-angiotensin-aldosterone system may require specific blockade of residual a Aldosterone as well as traditional angiotens in-converting enzyme inhibition.
Cardiovascular Drugs and Therapy?Escape? of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy
204 Citations1995B. Pitt
Journal of Cardiovascular PharmacologyAntihypertensive Therapy with MK 4211
193 Citations1982Jérôme Biollaz, Hans R. Brunner +3 more
Analysis of plasma angiotensin II-renin relationships strongly suggests that converting enzyme blockade is not complete even 4 h after 20 mg MK 421 and starts to wear off already at 12 h, which means MK 421 20 mg taken orally twice daily, effectively reduces blood pressure, but does not constantly suppress plasma angiotsin II and aldosterone.
European Heart JournalInverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients
190 Citations1998D. Duprez
In chronically treated heart failure patients with full angiotensin-converting enzyme-inhibition and diuretics, there is decreased compliance of the aorta and its major branches, which is inversely correlated with the aldosterone escape phenomenon.
HypertensionChronic administration of aldosterone depresses baroreceptor reflex function in the dog.
160 Citations1994Weizong Wang
The depressed baroreceptor function could be partially restored after a bolus injection of the Na+,K(+)-ATPase inhibitor ouabain (5 micrograms/kg i.v.).
ACC Current Journal ReviewThe effect of carvedilol on morbidity and mortality in patients with chronic heart failure
158 Citations1997
Carvedilol reduces the risk of death as well as the riskof hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting–enzyme inhibitor.
Journal of Clinical InvestigationAngiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion.
155 Citations1997Soichiro Okubo, Fumio Niimura +5 more
A powerful angiotensin-independent mechanism exists for the hyperaldosteronism during LS and high K is a central component of this mechanism, contrary to current belief, the tonic effect of high K on aldosterone synthesis and release does not require an intact renin-angiotens in system.
The LancetSuccesses and failures of current treatment of heart failure
141 Citations1998John G.F. Cleland, Karl Swedberg +1 more
The Journal of Clinical PharmacologyEvidence of a Partial Escape of Renin‐Angiotensin‐Aldosterone Blockade in Patients with Acute Myocardial Infarction Treated with Ace Inhibitors
138 Citations1993Claudio Borghi, Stefano Boschi +4 more
The present data suggest the existence of an interesting dissociation between the time‐course of ACE inhibition and that of blockade of the renin‐angiotensin system in patients with acute myocardial infarction.
The American Journal of CardiologyAldosterone and antialdosterone therapy in congestive heart failure
107 Citations1993Karl T. Weber, Daniel Villarreal
Antialdosterone therapy in patients with secondary hyperaldosteronism due to heart failure must achieve one or more of the following goals: reduce or, preferably, normalize plasma aldosterone levels by limiting synthesis; antagonize the renal and systemic effects of a Aldosterone at its receptor sites; and eliminate or minimize the multiple stimuli to ald testosterone secretion.
The American Journal of CardiologyRole of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation
49 Citations1993Didier Klug, V. Robert +1 more
The aldosterone antagonist spironolactone prevents myocardial fibrosis in several animal models, thus confirming the importance of ald testosterone in the genesis of excessive collagen deposition.
The American Journal of CardiologyAngiotensin-converting enzyme inhibitor and spironolactone combination therapy
38 Citations1993Faïez Zannad
Combined spironolactone and ACE inhibitors resulted in clinical improvement without serious side effects in patients who could not tolerate further increases in the ACE inhibitor dose, and anecdotal reports suggest.
EndocrinologyThapsigargin-Induced Increase in Cytoplasmic Ca<sup>2+</sup>Concentration and Aldosterone Production in Rat Adrenal Glomerulosa Cells: Interaction with Potassium and Angiotensin-II
29 Citations1991György Hajnóczky, Péter Várnai +5 more
The positive interaction between Tg and potassium on aldosterone production raises the possibility that stimuli generatingCa2+ signal by depleting intracellular Ca2+ stores, such as Tg or AII, enhance the response of the cell to depolarization.
Cleveland Clinic Journal of MedicineHigh or low doses of ACE inhibitors for heart failure?
14 Citations1998Robert E. Hobbs
Patients with heart failure who received a large daily dose of an angiotensin-converting inhibitor had a trend toward a lower mortality rate and the hospitalization rate was lower in the high-dose group, and the side-effect profile was the same in both groups.
Life SciencesInteractions between ouabain, atrial natriuretic peptide, angiotensin-II and potassium: Effects on rat zona glomerulosa aldosterone production
14 Citations1998Katalin Sz. Szalay, Monika Beck +2 more
Interactions between A-II, ANP, ouabain and potassium may be of physiological significance in the regulation of aldosterone secretion.